Published in Proc Natl Acad Sci U S A on June 01, 1983
The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol (1993) 2.87
Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med (1987) 2.28
Molecular cloning and characterization of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. Biochem J (1985) 2.19
Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med (2001) 1.91
Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A (1996) 1.91
Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A (1987) 1.68
Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol (2008) 1.52
P-selectin must extend a sufficient length from the plasma membrane to mediate rolling of neutrophils. J Cell Biol (1995) 1.52
Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol (2015) 1.52
Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J Exp Med (1988) 1.48
Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol (2011) 1.45
Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog (2008) 1.36
Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med (1989) 1.35
The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect Immun (2004) 1.25
Meningococcal disease and the complement system. Virulence (2013) 1.19
Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J Exp Med (1988) 1.16
Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo. J Virol (2000) 1.08
Functional characterization of LcpA, a surface-exposed protein of Leptospira spp. that binds the human complement regulator C4BP. Infect Immun (2010) 1.08
The amino-terminal module of the C4b-binding protein alpha-chain is crucial for C4b binding and factor I-cofactor function. Biochem J (1997) 1.04
Cloning of cDNA coding for the beta chain of human complement component C4b-binding protein: sequence homology with the alpha chain. Proc Natl Acad Sci U S A (1990) 1.04
Ultrastructure and composition of bovine conglutinin. Biochem J (1986) 1.02
Unusual ultrastructure of complement-component-C4b-binding protein of human complement by synchrotron X-ray scattering and hydrodynamic analysis. Biochem J (1986) 1.01
Concern Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation. Proc Natl Acad Sci U S A (2004) 1.00
Immune evasion of leptospira species by acquisition of human complement regulator C4BP. Infect Immun (2008) 1.00
Structural studies of proteins by high-flux X-ray and neutron solution scattering. Biochem J (1988) 0.94
Structural stability and heat-induced conformational change of two complement inhibitors: C4b-binding protein and factor H. Protein Sci (2004) 0.91
A theoretical model for the Gla-TSR-EGF-1 region of the anticoagulant cofactor protein S: from biostructural pathology to species-specific cofactor activity. J Comput Aided Mol Des (1997) 0.87
The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system. Biochem J (1991) 0.86
Human genes for the alpha and beta chains of complement C4b-binding protein are closely linked in a head-to-tail arrangement. Proc Natl Acad Sci U S A (1990) 0.82
Structure of the gene coding for the alpha polypeptide chain of the human complement component C4b-binding protein. J Exp Med (1991) 0.82
Expression and characterization of a recombinant C4b-binding protein lacking the beta-chain. Biochem J (1995) 0.81
Hijacking Complement Regulatory Proteins for Bacterial Immune Evasion. Front Microbiol (2016) 0.80
Protection of host cells by complement regulators. Immunol Rev (2016) 0.79
Cloning and characterization of a cDNA representing a putative complement-regulatory plasma protein from barred sand bass (Parablax neblifer). Biochem J (1994) 0.78
Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clin Exp Immunol (2009) 0.77
Molecular and cellular basis of deficiency of the b subunit for factor XIII secondary to a Cys430-Phe mutation in the seventh Sushi domain. J Clin Invest (1995) 0.77
LPS-Toll-Like Receptor-Mediated Signaling on Expression of Protein S and C4b-Binding Protein in the Liver. Gastroenterol Res Pract (2010) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Transfer of proteins across membranes. I. Presence of proteolytically processed and unprocessed nascent immunoglobulin light chains on membrane-bound ribosomes of murine myeloma. J Cell Biol (1975) 36.95
Regulation of glutamine synthetase. XII. Electron microscopy of the enzyme from Escherichia coli. Biochemistry (1968) 6.68
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry (1977) 2.77
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
Human C4-binding protein. I. Isolation and characterization. J Exp Med (1978) 2.60
Activation of the complement system by antibody-antigen complexes: the classical pathway. Adv Protein Chem (1979) 2.39
Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem (1980) 2.02
The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b. J Exp Med (1979) 1.97
Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. Biochem J (1983) 1.94
Cleavage of C4b by C3b inactivator: production of a nicked form of C4b, C4b', as an intermediate cleavage product of C4b by C3b inactivator. J Immunol (1980) 1.94
Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem (1981) 1.88
High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci U S A (1981) 1.83
Characterization of protein S, a gamma-carboxyglutamic acid containing protein from bovine and human plasma. Biochemistry (1979) 1.73
Circular polymerization of the ninth component of complement. Ring closure of the tubular complex confers resistance to detergent dissociation and to proteolytic degradation. J Biol Chem (1982) 1.70
Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. Biochem J (1983) 1.51
Ultrastructure of the membrane attack complex of complement: detection of the tetramolecular C9-polymerizing complex C5b-8. Proc Natl Acad Sci U S A (1982) 1.30
Ultrastructure of the first component of human complement: electron microscopy of the crosslinked complex. Proc Natl Acad Sci U S A (1982) 1.30
Changes in quaternary structure of IgG upon reduction of the interheavy-chain disulfide bond. Proc Natl Acad Sci U S A (1979) 1.19
Human C4-binding protein: N-terminal amino acid sequence analysis and limited proteolysis by trypsin. FEBS Lett (1982) 1.19
Degradation of human complement component C4b in the presence of the C4b-binding protein-protein S complex. Biochem J (1983) 1.14
Protein S, a new vitamin K-dependent protein from bovine plasma. FEBS Lett (1979) 1.14
Semi-flexible joint in the C1q subunit of the first component of human complement. J Mol Biol (1981) 1.08
Limited chymotryptic cleavage of human C4-binding protein: isolation of a carbohydrate-containing core domain and an active fragment. J Biochem (1982) 1.07
Preparation of human factor D of the alternative pathway of complement. Methods Enzymol (1981) 0.95
Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement. J Biol Chem (1982) 0.94
Murine binding protein of the fourth component of complement: structural polymorphism and its linkage to the major histocompatibility complex. Proc Natl Acad Sci U S A (1981) 0.88
Isolation of component C4 of human complement and its polypeptide chains. Eur J Biochem (1981) 0.81
A study of a covalent-like interaction between soluble nascent C4b and C4-binding protein. Biochim Biophys Acta (1982) 0.79
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
DNA repair in an active gene: removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall. Cell (1985) 7.62
Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med (1969) 7.43
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol (1970) 6.58
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 6.26
Complement. Annu Rev Biochem (1975) 6.00
DNA repair in bacteria and mammalian cells. Annu Rev Biochem (1979) 5.85
The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med (1968) 5.78
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Mechanism of antigen-driven selection in germinal centres. Nature (1990) 5.26
Chemistry and reaction mechanisms of complement. Adv Immunol (1968) 5.02
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
Sequence heterogeneity in closed simian virus 40 deoxyribonucleic acid. J Virol (1972) 4.69
X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4-. Biochemistry (1995) 4.64
Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med (1994) 4.63
Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med (1995) 4.34
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J (1997) 4.28
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med (1996) 4.07
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature (1990) 3.80
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
Bacteriophage and the toxigenicity of Clostridium botulinum type C. Science (1971) 3.63
Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature (1991) 3.61
Molecular regulation of apoptosis: genetic controls on cell death. Cell (1993) 3.57
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest (1970) 3.55
Complement. Annu Rev Biochem (1969) 3.51
Incompatibility group P plasmids: genetics, evolution, and use in genetic manipulation. Annu Rev Microbiol (1987) 3.47
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Preferential DNA repair of an active gene in human cells. Proc Natl Acad Sci U S A (1986) 3.42
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Molecular analysis of the membrane attack mechanism of complement. J Exp Med (1972) 3.35
Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med (1967) 3.28
Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol (1971) 3.25
C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med (1975) 3.21
Lysis of erythrocytes by complement in the absence of antibody. J Exp Med (1970) 3.19
Patterns of cognitive appraisal in emotion. J Pers Soc Psychol (1985) 3.14
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 3.11
Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol (1993) 3.03
The hydrophobicity of bacteria - an important factor in their initial adhesion at the air-water interface. Arch Microbiol (1981) 3.02
Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement. J Immunol (1966) 2.98
Are we vaccinating too much? J Am Vet Med Assoc (1995) 2.97
The ninth component of human complement: isolation, description and mode of action. Immunology (1969) 2.96
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med (1974) 2.93
Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis. Immunology (1967) 2.93
Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet (1996) 2.92
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
Characterization of a murine lymphokine distinct from interleukin 2 and interleukin 3 (IL-3) possessing a T-cell growth factor activity and a mast-cell growth factor activity that synergizes with IL-3. Proc Natl Acad Sci U S A (1986) 2.84
The role of properdin in the alternate pathway of complement activation. J Exp Med (1974) 2.77
Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med (1966) 2.73
A lymphotoxin-beta-specific receptor. Science (1994) 2.73
Form C of the MHLC scales: a condition-specific measure of locus of control. J Pers Assess (1994) 2.69
The importance of timing: the varying impact of childhood and adolescent maltreatment on multiple problem outcomes. Dev Psychopathol (2001) 2.67
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med (1973) 2.64
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity (1994) 2.59
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
The membrane attack complex of complement. Annu Rev Immunol (1986) 2.57
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Linkage scores and corrections in simple two- and three-generation families. Ann Hum Genet (1968) 2.52
Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med (1973) 2.50
Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med (1997) 2.46
The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution. J Exp Med (1973) 2.44
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
In vivo effects of intercalating drugs on the superhelix density of mitochondrial DNA isolated from human and mouse cells in culture. J Mol Biol (1971) 2.44
Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A (1986) 2.39
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
Long-term outcome in children after antenatal intervention for obstructive uropathies. Lancet (1999) 2.37
Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ (2008) 2.36
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Activation of the contact-phase system on bacterial surfaces--a clue to serious complications in infectious diseases. Nat Med (1998) 2.32
Apoptosis: molecular regulation of cell death. Eur J Biochem (1996) 2.29
Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med (1995) 2.28
Comparative analysis of binding of human damaged DNA-binding protein (XPE) and Escherichia coli damage recognition protein (UvrA) to the major ultraviolet photoproducts: T[c,s]T, T[t,s]T, T[6-4]T, and T[Dewar]T. J Biol Chem (1993) 2.28
The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency. J Exp Med (1969) 2.25
Studies on the nature of the chloroplast lamella. I. Preparation and some properties of two chlorophyll-protein complexes. Biochemistry (1967) 2.25
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood (2001) 2.20
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Occurrence of complex mitochondrial DNA in normal tissues. Nature (1968) 2.18
A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity (2001) 2.16
Cytotoxic effects of leukocyres triggered by complement bound to target cells. Science (1969) 2.15
Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med (1976) 2.13
Complement: substitution of the terminal component in immune hemolysis by 1,10-phenanthroline. Science (1967) 2.11
Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell (1993) 2.11
A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A (1976) 2.09